|4May 11, 5:07 PM ET

Ajdler Arnaud 4

4 · Recro Pharma, Inc. · Filed May 11, 2020

Insider Transaction Report

Form 4
Period: 2020-05-07
Transactions
  • Award

    Common Stock

    2020-05-07+8,36323,757 total
  • Award

    Stock Option (right to buy)

    2020-05-07+12,40512,405 total
    Exercise: $8.37Exp: 2030-05-07Common Stock (12,405 underlying)
Holdings
  • Common Stock

    (indirect: See footnote)
    1,104,546
Footnotes (3)
  • [F1]All shares of common stock are represented by unvested restricted stock units that will vest on May 7, 2021. Vested shares will be delivered to the reporting person within 30 days following the vesting date.
  • [F2]The Reporting Person is the managing partner of Engine Capital Management, LP ("Engine Management") and the Managing Member of each of Engine Capital Management GP, LLC ("Engine Management GP") and Engine Investments, LLC ("Engine Investments"). Engine Management GP is the investment manager of Engine Capital, L.P. ("Engine Capital") and Engine Jet Capital, L.P. ("Engine Jet Capital"). Engine Capital and Engine Jet Capital own 907,578 and 196,968 shares of the Issuer's common stock, respectively. The Reporting Person disclaims beneficial ownership in such securities except to the extent of his pecuniary interest therein.
  • [F3]The stock option will vest on May 7, 2021.

Documents

1 file
  • 4
    edgar.xmlPrimary

    PRIMARY DOCUMENT